Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIST COPD-1
jRCT2031260459Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GSK5784283 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SHR-1905
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031260459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260459.